We are live on ! Find out more
OCA

Octagon Capital Advisors Portfolio holdings

AUM $904M
1-Year Est. Return 737.04%
This Fund
S&P 500
This Quarter Est. Return
-2.36%
1 Year Est. Return
+737.04%
3 Year Est. Return
+2,554.78%
5 Year Est. Return
+4,333.84%
10 Year Est. Return
–
AUM
$651M
AUM Growth
-$67.8M
Cap. Flow
+$76.4M
Cap. Flow %
11.74%
Top 10 Hldgs %
67.67%
Holding
49
New
8
Increased
13
Reduced
11
Closed
9

Top Buys

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$22.5M
2
INSM icon
Insmed
INSM
+$21M
3
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$14.7M
4
INZY
Inozyme Pharma
INZY
+$6.36M
5
DNTH icon
Dianthus Therapeutics
DNTH
+$5.61M

Top Sells

Rank Stock Value
1
CBAY
Cymabay Therapeutics
CBAY
+$19.8M
2
IRON icon
Disc Medicine
IRON
+$18.4M
3
TNDM icon
Tandem Diabetes Care
TNDM
+$11.7M
4
GERN icon
Geron
GERN
+$7.31M
5
BBIO icon
BridgeBio Pharma
BBIO
+$7.03M

Sector Composition

Rank Sector Weight
1 Healthcare 87.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APLS
1
DELISTED
Apellis Pharmaceuticals
APLS
$119M 18.29%
3,130,000
+511,700
+20% +$22.5M
ROIV icon
2
Roivant Sciences
ROIV
$25.2B
$51M 7.84%
4,367,000
+463,000
+12% +$5.23M
CBAY
3
DELISTED
Cymabay Therapeutics
CBAY
$45.8M 7.04%
3,073,750
-1,497,168
-33% -$19.8M
VRNA
4
DELISTED
Verona Pharma
VRNA
$38.6M 5.93%
2,369,000
-99,000
-4% -$1.91M
IMVT icon
5
PUT
Immunovant
IMVT
$8.09B
$38.4M 5.9%
+1,000,000
New +$22.6M
RCUS icon
6
Arcus Biosciences
RCUS
$3.57B
$35.3M 5.43%
1,968,000
– –
INSM icon
7
Insmed
INSM
$23.2B
$32.4M 4.98%
1,284,000
+917,000
+250% +$21M
MRTX
8
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$28.5M 4.38%
655,051
-94,949
-13% -$3.39M
APLS
9
PUT
DELISTED
Apellis Pharmaceuticals
APLS
$25.7M 3.94%
+675,000
New +$29.7M
BBIO icon
10
BridgeBio Pharma
BBIO
$16.5B
$25.6M 3.94%
971,639
-247,561
-20% -$7.03M
CLDX icon
11
Celldex Therapeutics
CLDX
$2.77B
$20.9M 3.21%
759,898
– –
ETNB
12
DELISTED
89bio
ETNB
$18.8M 2.89%
1,219,157
+152,373
+14% +$2.56M
OKUR
13
OnKure Therapeutics
OKUR
$166M
$17.4M 2.67%
227,987
-8,872
-4% -$603K
VRDN icon
14
Viridian Therapeutics
VRDN
$2.13B
$16.4M 2.52%
1,067,143
+144,143
+16% +$2.75M
APLS
15
CALL
DELISTED
Apellis Pharmaceuticals
APLS
$15.2M 2.34%
+400,000
New +$17.6M
ANTX icon
16
AN2 Therapeutics
ANTX
$177M
$14M 2.14%
867,575
+146,675
+20% +$1.66M
AMLX icon
17
Amylyx Pharmaceuticals
AMLX
$2.05B
$12.7M 1.96%
+695,000
New +$14.7M
TSHA icon
18
Taysha Gene Therapies
TSHA
$1.59B
$8.78M 1.35%
+2,777,778
New +$5.19M
ALPN
19
DELISTED
Alpine Immune Sciences Inc
ALPN
$8.59M 1.32%
750,000
– –
GOSS icon
20
Gossamer Bio
GOSS
$66.5M
$6.82M 1.05%
8,187,883
+4,229,814
+107% +$4.87M
JBIO
21
Jade Biosciences
JBIO
$1.22B
$6.75M 1.04%
14,211
-3,552
-20% -$1.92M
DNTH icon
22
Dianthus Therapeutics
DNTH
$5.68B
$6.56M 1.01%
480,000
+445,625
+1,296% +$5.61M
DYN icon
23
Dyne Therapeutics
DYN
$4.04B
$6.21M 0.95%
692,945
– –
PMVP icon
24
PMV Pharmaceuticals
PMVP
$66.1M
$5.55M 0.85%
904,000
+434,000
+92% +$2.98M
INZY
25
DELISTED
Inozyme Pharma
INZY
$5.46M 0.84%
1,300,000
+1,250,298
+2,516% +$6.36M
1
2

Similar funds

AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
AOWM
Asset One Wealth Management Bellevue, Washington $904M AUM
SWM
Sendero Wealth Management San Antonio, Texas $904M AUM 22.78% 1-Year Est. Return
EI
EnCap Investments Houston, Texas $905M AUM
PIP
Permian Investment Partners Dallas, Texas $905M AUM 13.43% 1-Year Est. Return
PSCM
Per Stirling Capital Management Austin, Texas $905M AUM 17.06% 1-Year Est. Return
EWM
Evermay Wealth Management Arlington, Virginia $902M AUM 14.76% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

Octagon Capital Advisors's Q3 2023 Portfolio in Review

As of Q3 2023, Octagon Capital Advisors held 49 positions worth $651M, down 9.4% from $719M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Octagon Capital Advisors deployed $76.4M of net new capital in Q3 2023, opening 8 new positions and adding to 13 existing holdings. Its largest new stake was Amylyx Pharmaceuticals: 695,000 shares worth $12.7M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was Cymabay Therapeutics, an estimated $19.8M trimmed.

  • Octagon Capital Advisors's largest Q3 2023 buy was Amylyx Pharmaceuticals: 695,000 shares worth $12.7M.
  • Octagon Capital Advisors added most to Apellis Pharmaceuticals in Q3 2023, an estimated $22.5M increase.
  • Octagon Capital Advisors's biggest Q3 2023 reduction was Cymabay Therapeutics, cutting an estimated $19.8M.
  • Octagon Capital Advisors fully exited Disc Medicine in Q3 2023, selling an estimated $18.4M.
  • Octagon Capital Advisors's ten largest holdings make up 68% of its $651M portfolio in Q3 2023.
  • Octagon Capital Advisors opened 8 new positions and closed 9 in Q3 2023.
  • Octagon Capital Advisors's portfolio value fell 9.4% quarter-over-quarter to $651M.

Based on Octagon Capital Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.